| Literature DB >> 23575112 |
Alessandro Paiardini1, Stefano Pascarella.
Abstract
BACKGROUND: Autoimmune hepatitis (AIH) is a chronic, progressive liver disease, characterized by continuing hepatocellular inflammation and necrosis. A subgroup of AIH patients presents specific autoantibodies to soluble liver antigen/liver-pancreas (SLA/LP) protein, which is regarded as a highly specific diagnostic marker. Autoantigenic SLA/LP peptides are targeted by CD4+ T cells, and restricted by the allele HLA-DRB1*03:01, which confers disease susceptibility in Europeans and Americans. A positively charged residue at position 71 has been indicated as critical for AIH susceptibility in all of the HLA alleles identified to date. Though the exact molecular mechanisms underlying pathogenesis of AIH are not clear, molecular mimicry between SLA/LP and viral/bacterial antigens has been invoked.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23575112 PMCID: PMC3636016 DOI: 10.1186/1742-4682-10-25
Source DB: PubMed Journal: Theor Biol Med Model ISSN: 1742-4682 Impact factor: 2.432
Figure 1Sequence comparison between the autoepitope of SLA/LP and the corresponding region of the 120 KDa surface antigen from Sequence comparison between the region encompassing the autoepitope of the human SLA/LP antigen [UniProt:Q9HD40] and the portion of the 120 KDa surface antigen from Rickettsia prowazekii [UniProt:Q9ZD49]. Numbers attached to the accession codes indicate the sequence positions of the displayed segments within the respective entire sequences. Amino acid letters are colored according to conservation and physico-chemical properties. Annotations below alignment indicate the respective predicted secondary structure (red bars represent α-helices) and solvent accessibility. Sequence positions corresponding to B letters in the lines labeled 25% are predicted to expose to the solvent less than 25% of their total area. The black bar atop sequences denotes the peptide interacting with HLA-DRB1*03:01.
Figure 2Modeling of the interaction between HLA-DRB1*03:01, SLA/LP, and PS 120. A) The crystal structure of HLA-DRB1*03:01 is represented as ribbons and transparent surface, with carbon atoms colored in light grey, oxygen in red, nitrogen in blue and sulfur in yellow. SLA/LP452-465 (peptide “A”) and PS 120790-804 (peptide “B”) are depicted as cyan and brown sticks, respectively. The location of anchoring pockets P1, P4, P6 and P9 is also indicated. B) Detail of the P4 binding cleft. This figure was rendered with PyMOL [35].
Top 10 hot spots of interaction (according to free energy of binding) between HLA-DRB1*03:01, human SLA/LP, and the corresponding PS 120from
| Asp B57 | Arg 462 | −7.382 |
| Glu A55 | Arg 453 | −5.015 |
| Asp A66 | Lys 459 | −4.108 |
| Glu B9 | Lys 549 | −2.518 |
| Arg A76 | Arg 465 | −2.381 |
| Leu B53 | Arg 462 | −2.013 |
| Ser B11 | Lys 459 | −1.879 |
| Tyr B78 | Cys 457 | −1.158 |
| Val B85 | Leu 454 | −1.130 |
| Phe A54 | Leu 454 | −1.081 |
| Lys B71 | Glu 795 | −5.191 |
| Asp A66 | Lys 797 | −3.279 |
| Arg B74 | Glu 795 | −3.153 |
| Glu B9 | Lys 797 | −2.671 |
| Arg B74 | Leu 796 | −1.972 |
| Asp B57 | Asn 800 | −1.425 |
| Tyr B61 | Ile 801 | −1.235 |
| Glu A55 | Arg 794 | −1.211 |
| Phe A54 | Leu 792 | −1.121 |
| Val B85 | Leu 792 | −1.057 |